The Opdivo (nivolumab) Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The size of the opdivo (nivolumab) market has exhibited significant growth in recent years. The market size is projected to increase from $7,709.49 million in 2024 to $8,335.54 million in 2025. This represents a compound annual growth rate (CAGR) of 8.1%.
The opdivo (nivolumab) market is forecasted to be worth $11,281.56 million in 2029, growing at a compound annual growth rate (CAGR) of 7.9%.
Download Your Free Sample of the 2025 Opdivo (nivolumab) Market Report and Uncover Key Trends Now!The key drivers in the opdivo nivolumab market are:
• Rising incidence of non-small cell lung cancer globally
• High prevalence due to factors like smoking, environmental pollutant exposure and genetic mutations
• Increase in a family history of cancer being discovered
• The ability of Opdivo to enhance the body's immune response to attack cancer cells.
The opdivo (nivolumab) market covered in this report is segmented –
1) By Type: 40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL
2) By Dosage: Injection, Solution, Other Dosages
3) By Demographic: Adult, Pediatric
4) By Application: Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications
5) By End-User: Hospitals, Clinics, Other End Users
The key trends in the opdivo nivolumab market are:
• Pegylated products are being increasingly adopted across the market.
• Personalized medicine and targeted therapies are shaping future trends.
• Technological advancements in asparaginase formulation are gaining traction.
• There is a growing demand for biosimilar alternatives.
Major players in the opdivo nivolumab market are:
• Br
North America is the leading region in the Opdivo (nivolumab) market as of 2024.